Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.
Department of Dermatology, Universitätsklinikum Erlangen, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048.
Actinic keratoses (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guideline "actinic keratosis and cutaneous squamous cell carcinoma" was developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, policy makers and insurance funds. In the first part, we will address aspects relating to diagnosis, interventions for AK, care structures and quality-of-care indicators.
光化性角化病(AK)是浅色皮肤个体中常见的病变,可能会进展为皮肤鳞状细胞癌(cSCC)。这两种情况都可能导致严重的发病率,并构成重大的疾病负担,尤其是在老年人中。为了为临床决策制定建立一个基于证据的框架,根据德国科学医学协会联合会(AWMF)发布的规定,使用最高水平的方法学(S3)制定了“光化性角化病和皮肤鳞状细胞癌”指南。该指南针对的是皮肤科医生、全科医生、耳鼻喉科专家、外科医生、肿瘤学家、放射科医生和放射肿瘤学家,以及参与 AK 和 cSCC 患者诊断和治疗的其他医学专业人员。该指南还针对受影响的患者、他们的亲属、政策制定者和保险基金。在第一部分中,我们将讨论与 AK 的诊断、干预措施、护理结构和质量指标相关的方面。